• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

11.14 +0.19 (+1.78%)
Streaming Delayed Price Updated: 2:25 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
January 14, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
January 12, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
January 08, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
January 08, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
January 07, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
December 12, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
November 18, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
November 12, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
October 28, 2025
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
October 08, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
September 24, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
September 19, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
September 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
September 09, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
September 02, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
August 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
August 27, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
August 21, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
August 06, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
July 28, 2025
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
July 28, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
July 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
July 08, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
July 02, 2025
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
June 23, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Addition to Russell 3000® Index
June 20, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
June 05, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap